Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl… Read more
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.45 Billion INR
Based on the latest financial reports, Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) has total liabilities worth ₹1.45 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aarey Drugs & Pharmaceuticals Limited - Total Liabilities Trend (2009–2025)
This chart illustrates how Aarey Drugs & Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aarey Drugs & Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Aarey Drugs & Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Equus Energy Ltd
AU:EQU
|
Australia | AU$159.97K |
|
iOThree Limited Ordinary Shares
NASDAQ:IOTR
|
USA | $4.88 Million |
|
Big Ridge Gold Corp
OTCQB:ALVLF
|
USA | $1.38 Million |
|
GFM Services Bhd
KLSE:0039
|
Malaysia | RM422.88 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Aarey Drugs & Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aarey Drugs & Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aarey Drugs & Pharmaceuticals Limited (2009–2025)
The table below shows the annual total liabilities of Aarey Drugs & Pharmaceuticals Limited from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹997.86 Million | -41.48% |
| 2024-03-31 | ₹1.71 Billion | -1.95% |
| 2023-03-31 | ₹1.74 Billion | +32.22% |
| 2022-03-31 | ₹1.32 Billion | -1.97% |
| 2021-03-31 | ₹1.34 Billion | +31.88% |
| 2020-03-31 | ₹1.02 Billion | +71.96% |
| 2019-03-31 | ₹591.63 Million | -33.93% |
| 2018-03-31 | ₹895.47 Million | -3.62% |
| 2017-03-31 | ₹929.07 Million | +5.22% |
| 2016-03-31 | ₹883.00 Million | +11.01% |
| 2015-03-31 | ₹795.40 Million | +9.91% |
| 2014-03-31 | ₹723.68 Million | -1.74% |
| 2013-03-31 | ₹736.46 Million | +36.32% |
| 2012-03-31 | ₹540.24 Million | +160.25% |
| 2011-03-31 | ₹207.59 Million | +22.74% |
| 2010-03-31 | ₹169.12 Million | +141.39% |
| 2009-03-31 | ₹70.06 Million | -- |